Prestige Consumer Healthcare launches $400 million notes offering to refinance 2028 debt

Prestige Consumer Healthcare Inc. said on July 6, 2026 that its subsidiary Prestige Brands, Inc. was preparing to offer up to $400 million in new senior notes due 2034 through a private placement, subject to market conditions.¹ The notes would rank as senior unsecured debt of Prestige Brands, with guarantees from the parent company and certain domestic subsidiaries.¹

According to the release, the company planned to combine the offering's proceeds with cash on hand to fully redeem the $400 million in outstanding 5.125% Senior Notes due 2028, covering associated costs along the way.¹ Prestige Brands said it would formally notify holders of its plan to redeem the 2028 notes at full face value plus accrued interest, though that redemption depends on completing a new offering of at least $400 million in senior notes.¹ The company retains discretion to waive that financing condition.¹

The notes offering was limited under securities law: it targeted only qualified institutional buyers under Rule 144A, or non-U.S. persons under Regulation S.¹

Separately, the filing disclosed that on July 1, 2026, Prestige Brands amended its Term Loan Credit Agreement, arranged by Citibank, N.A., Barclays Bank PLC, Morgan Stanley Senior Funding Inc., Goldman Sachs Bank USA and RBC Capital Markets.¹ The amendment allowed Prestige Brands to borrow up to $95.0 million in additional term loans to help fund its acquisition of several Australian entities operating under the LaCorium Health brand.¹ The company borrowed the full $95,000,000 on the closing date to finance that acquisition, which closed the same day.¹

A second press release on July 6, 2026 confirmed the completion of the LaCorium acquisition along with pricing of the private notes offering.¹